Volasertib for AML: clinical use and patient consideration

Zhonglin Hao, Georgia Regents University
Vamsi Kota, Emory University

Journal Title: OncoTargets and Therapy
Publisher: Dove Medical Press | 2015-07, Pages 1761-1761
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.2147/OTT.S60762
Permanent URL: https://pid.emory.edu/ark:/25593/qj112

Final published version: http://dx.doi.org/10.2147/OTT.S60762

Copyright information:
© 2015 Hao and Kota.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Accessed September 11, 2020 9:53 AM EDT
Volasertib for AML: clinical use and patient consideration

Zhonglin Hao1
Vamsi Kota2
1Cancer Center, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA; 2Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA

Abstract: Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients >65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy.

Keywords: volasertib, acute myeloid leukemia, management, induction

Introduction
Acute myeloid leukemia (AML) is a clonal hematological disorder characterized by proliferation of immature cells. This increased proliferation leads to cytopenias, which commonly present with neutropenia leading to infections, thrombocytopenia leading to bleeding complications, and anemia presenting as dyspnea on exertion or at rest.1 The incidence of AML increases with age, with the median age of diagnosis being 65–70 years.2 The cytopenias and the elderly age at presentation complicate the treatment with standard induction, showing very poor survival at 2 years.2 Even for patients of younger age (<60 years), the standard-of-care treatments have not changed significantly for the better in the past. Anthracycline and cytarabine combination is still considered the first-line treatment.3 This is one of the main reasons for the continued investigation of newer drugs in the treatment of AML. This article covers approaches to the elderly and the infirm patients with AML and reviews in depth the new cell cycle inhibitor volasertib, its mechanism of action, pharmacology, and its promise in becoming the standard of care for elderly and infirm patients with AML.

Risk stratification and current management of AML
Chromosomal evaluation has long played an important role in risk stratification of AML patients.4 On the basis of whether patients have abnormal cytogenetics or according to the types of abnormal cytogenetics in the leukemia blasts, AML is stratified into four different risk groups: Favorable, Intermediate I, Intermediate II, and Adverse risk groups.4

Induction therapies are similar in all patients. However, postremission care may vary, with allogeneic stem cell transplant being the preferred option in poor and some intermediate risk groups. The favorable-risk AML patients generally are expected to do well with postremission consolidation chemotherapy alone.5,6 Acute promyelocytic
leukemia, which is characterized by translocation (15:17) in most patients and variant translocation involving chromosome 17 in others, is a unique subset and is treated differently. All-trans retinoic acid and arsenic trioxide have been shown to be very effective as frontline treatments in patients presenting with white cell counts <10,000/mL. This subset of AML can be considered one of the first cancers for which targeted therapy has been used successfully. Cure has been achieved in a significant proportion of patients in this group. Identification of this subset has allowed us to tailor the treatments to this type of AML and laid the foundation for our approach to AML, which is increasingly recognized, genetically, as a very heterogeneous disease.

Genetics and epigenetics in AML: understanding the heterogeneity of AML

Cytogenetic evaluation has been the cornerstone of risk stratification, but 50% of patients have “normal cytogenetics”, making this one the largest subsets of all AML patients. Further classification of these patients has been increasingly pursued both for prognostic reasons and for better identification of patients who will benefit from targeted therapies. The advent of molecular diagnostics has increased our understanding of the genetic heterogeneity of this disease. The most recent European LeukemiaNet (ELN) guidelines now incorporate the mutational status of internal tandem duplications (ITDs) in FLT3 (encoding fms-related tyrosine kinase 3), CEBPA (encoding CCAAT/enhancer binding protein (C/EBP), alpha), and NPM1 (encoding nucleophosmin) into risk stratification considerations, which allows us to better direct care specifically to the intermediate-risk group for AML. Other than identifying the driver mutations of disease, another advantage of identifying these mutations might be in the monitoring of minimal residual disease (MRD). Although it has not been validated for all mutations yet, NPM1 mutation has been shown to be useful in monitoring MRD.

NPM1 is the most common mutation detected in AML. It is found in 25%–30% of all AML patients and in 45%–50% of patients who are cytogenetically normal (CN). This mutation has been well documented to confer chemosensitivity and is generally considered to be a good prognostic marker. Although it is widely accepted to be a valid good prognostic marker in all age groups, some emerging data suggest that in patients older than 65 years of age, this mutation might not have as good outcomes. If confirmed, alternative treatment practices might need to be considered even with this mutation. Present practice withholds allogeneic transplant in patients with this mutation regardless of age. The concurrent presence of the FLT3-ITD mutation also leads to poor outcomes in NPM1-mutated patients.

FLT3-ITD mutations are present in approximately one-third of all CN-AML patients. Presence of such mutations is widely accepted to confer poor outcome in AML. The allelic burden of this mutation seems to be important prognostically as well, with high allelic burden having worse outcomes. However, the importance of lower burden is still a matter of controversy. A different insertion point at the tyrosine kinase domain, hence labeled as FLT3-TKD, also confers a worse outcome. Multiple drugs are being investigated as potential inhibitors of FLT3. So far, however, the results have been with varying success.

CEBPA is a less common mutation as compared to NPM1 and FLT3-ITD. It confers better prognosis, although only double mutations can be considered significant. This mutation is also commonly seen in association with NPM1 or FLT3-ITD. The outcome might be different when it is associated with FLT3-ITD.

DNMT3A (encoding DNA (cytosine-5-)-methyltransferase 3 alpha) mutations are seen in approximately one-third of all CN-AML patients. These mutations appear to confer worse outcomes. There are, however, some conflicting studies on the effects in younger patients. In a recent study, younger patients who had this mutation appeared to have benefited from increasing doses of anthracycline.

IDH1 and IDH2 (isocitrate dehydrogenases 1 and 2) are mutated in approximately 25% of CN-AML patients. Although the prognostic significance is still debated, availability of targeted therapy inhibiting these mutations might allow us to better treat these patients if ongoing studies show a favorable outcome.

TET2 (tet methylcytosine dioxygenase 2) and ASXL1 mutations are less common mutations in AML. Both appear to be more common with increasing age among AML patients. ASXL1 mutations appear to confer a poor outcome, and the prognostic significance of the TET2 mutation is still controversial, with studies showing conflicting results on overall survival (OS).

Standard-of-care treatment

The standard-of-care treatment for AML includes an upfront induction therapy, followed by a risk-adapted consolidation therapy. Induction chemotherapy for AML patients who can tolerate intensive treatment generally consists of combinations of an anthracycline with cytarabine. Various trials have
been conducted to add additional drugs to this combination, but none of them showed any significant benefit to change the clinical practice.\textsuperscript{23} Studies conducted on changing the dose of cytarabine or anthracycline (daunorubicin versus idarubicin) did not show any consistent benefit. As a result, a single regimen has become the standard of care that is widely used.\textsuperscript{24,25} A recent study comparing daunorubicin 90 mg/m\textsuperscript{2} to 45 mg/m\textsuperscript{2} in patients younger than 60 years of age showed the superiority of the higher dose, and this regimen is increasingly being used in the community.\textsuperscript{26} A similar study comparing a higher dose to the conventional dose of daunorubicin showed that the higher dose achieved better responses in elderly patients.\textsuperscript{27} The goal of induction treatments is to achieve a complete remission (CR). The latter is traditionally defined as bone marrow blasts $\leq$5% and recovery in blood counts with absolute neutrophil count of $>1,000$ × 10\textsuperscript{9}/mL and platelets $>100,000$ × 10\textsuperscript{9}/mL. The rate of CR in younger patients with the high-dose daunorubicin/cytarabine combination approaches 70% after one cycle of induction as compared to 50%–60% CR rates with the standard dose of daunorubicin.

Many more trials were conducted with varying doses of cytarabine. However, 100–200 mg/m\textsuperscript{2} of cytarabine daily for 7 days as continuous infusion is considered the conventional dose along with daunorubicin or idarubicin for the first 3 days. Higher doses of cytarabine have been tested. Although some studies have suggested relapse-free survival (RFS) benefit, large randomized studies have not shown an OS advantage. The common practice is still a conventional dose of cytarabine for induction in both the young- and the older-aged patients.\textsuperscript{28}

**Older adults**

The induction treatment of AML in elderly patients, which generally refers to those older than 65 years of age, is much more complicated, although this is the more commonly seen patient population with this disease. In patients who can tolerate intensive chemotherapy, induction with high-dose daunorubicin and cytarabine has been shown to be beneficial in achieving CR. Unfortunately, most patients are not eligible for induction therapy due to age and performance status. Large cooperative group studies carried out by the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), and the UK National Cancer Research Institute (NCRI) showed that the probability of 2-year survival in elderly patients undergoing intensive treatment is only approximately 20%–25%, with CR rates after induction of approximately 40%–50%. The high rate of induction mortality (15%–19%) might be one reason for the poor outcomes. These survival data again included only patients who were considered to be well enough to receive intensive treatments.\textsuperscript{29–31} Various prognostic models are being developed to help us choose patients for induction therapy as induction therapy still offers the best chance of achieving remission in patients who can tolerate it.\textsuperscript{32,33}

In addition, it is well known that older age has been associated with a decrease in the number of patients with favorable cytogenetics, from 30% to only 7%, and doubling of complex cytogenetics, from 6% to 12%. As a result, the 5-year survival is only 13% compared with 57% in the youngest age group.\textsuperscript{34} This means that therapeutic agents such as volasertib that work across different cytogenetic risk groups are expected to offer an advantage in the treatment of AML in elderly patients because current agents are frequently ineffective in the complex cytogenetic group (refer section on “Consolidation therapy”).

**Consolidation therapy**

In patients who achieve CR after induction therapy, lack of additional treatments invariably leads to relapse of disease in almost all patients.\textsuperscript{35} Ever since the Cancer and Leukemia Group B presented the landmark results in 1994 showing superiority of high-dose cytarabine (3 g/m\textsuperscript{2}) versus intermediate dose (400 mg/m\textsuperscript{2}) versus low dose (100 mg/m\textsuperscript{2}), it has become the standard of care in most practices. This high dose is given every 12 hours on Days 1, 3, and 5.\textsuperscript{36} Newer studies with lower doses (1.5 g/m\textsuperscript{2}) have shown similar benefit with less toxicity. Therefore, lower doses can also be used in consolidation treatment. The number of cycles is not clearly established, although it is common to give three to four cycles.\textsuperscript{37}

Consolidation therapy in elderly patients who tolerated induction and are eligible to receive intensive therapy again is probably best limited to one to two cycles of consolidation, with 1.0–1.5 g/m\textsuperscript{2} of cytarabine over 4–6 days in each cycle. Another option can be as per the recent Acute Leukemia French Association (ALFA) 98 trial documenting the superiority of the ambulatory arm. This regimen consisted of an anthracycline (idarubicin 90 mg/m\textsuperscript{2} or daunorubicin 45 mg/m\textsuperscript{2}) for 1 day and 60 mg/m\textsuperscript{2} of cytarabine every 12 hours for 5 days each month for 6 months.\textsuperscript{38}

Postremission management should include discussions of allogeneic stem cell transplant in all patients with intermediate or poor risk of disease, classified as such per the new ELN guidelines. Age alone need not be an exclusion criterion, with most transplant centers routinely considering transplants up to the age of 70 years. The Hematopoietic Cell Transplantation Comorbidity Index has been shown...
to be a good predictor of outcomes based on pretransplant comorbidities.\textsuperscript{39}

\textbf{Pitfalls of standard chemotherapy}

As noted earlier, AML is a disease of the elderly population, with more than half of all patients being above 65 years of age. Unfortunately, the disease biology appears to be different in the elderly, with higher chance of antecedent myelodysplastic syndromes (MDS), higher chance of multidrug resistance, and poor performance status. An evaluation of patients enrolled under the SWOG trials showed that patients older than 66 years of age had a 20\% chance of mortality within 30 days, and this mortality rate was even higher for patients over the age of 75 years. This high mortality was seen even in patients with good performance status.\textsuperscript{40} Therefore, alternative low-intensiveness therapies were vigorously sought.

It is also widely recognized that patients enrolled in clinical trials comprise a selected group of patients, and it is likely that the outcomes would be worse if the same intensive treatments were applied to those in the general population. Patients treated on a clinical trial are likely to be given curative intent treatment and their outcomes are likely to be better. This might not be extrapolated to the general population as it is likely that patients in that age group have comorbid conditions. These patients with comorbid conditions are frequently excluded from clinical trials.\textsuperscript{41} A recent Surveillance, Epidemiology and End Results (SEER) and Medicare review of outcomes of patients with AML showed that 60\% of patients are not offered any of the standard recommended options of chemotherapy, including hypomethylating therapy.\textsuperscript{42} Thus, the availability of newer agents that are better tolerated might change this approach in clinical practice even in the elderly or in patients with comorbid conditions who are routinely deemed unfit for any treatments. At least four options are currently available or are being studied, as described in the following sections.

\textbf{Low-dose Ara-C}

For the elderly and infirm patients deemed unable to tolerate the standard induction chemotherapy with an anthracycline and cytarabine combination, low-dose cytarabine (low-dose Ara-C or LDAC) is better than supportive care. This was shown in a Phase III trial in 2007 comparing LDAC and hydroxyurea (HU).\textsuperscript{43} In this trial, LDAC offered 18\% CR rate compared to only 1\% in the HU arm ($P=0.00006$). Most importantly, those who received LDAC had OS advantage relative to HU recipients (hazard ratio [HR]: 0.60; 95\% confidence interval [CI]: 0.44–0.81; $P=0.0009$). LDAC is commonly used for this group of patients.

\textbf{Hypomethylating agents in AML}

Azacitidine and decitabine are approved in the USA for the treatment of MDS. Decitabine is also approved in the European Union for the newly diagnosed de novo or secondary AML in patients aged $\geq65$ years or for those who cannot tolerate standard induction chemotherapy. These agents are well tolerated, and the response rates are only slightly better as compared to the best supportive care plus low-dose cytarabine in most patients. Patients with low blast counts in the range of 20\%–30\% appear to benefit more from these agents as compared to patients with a very high disease burden. These are good results as compared to available chemotherapy options. In addition, patients with complex cytogenetics and $TP53$ mutations are especially suited for such option given their poor response to conventional chemotherapy.\textsuperscript{44} A Phase III study compared decitabine with supportive care or LDAC in patients aged 65 years or older with newly diagnosed AML in the poor- or intermediate-risk category.\textsuperscript{45} The CR and CR without platelet recovery (CRp) were 17.8\% versus 7.8\% (odds ratio [OR]: 2.5; 95\% CI: 1.4–4.8; $P=0.001$). Although there was no difference in OS per protocol analysis (7.7 months versus 5.0 months; HR: 0.85; 95\% CI: 0.69–1.04; $P=0.108$), unplanned analysis based on mature survival data did show significant OS benefit (HR: 0.82; 95\% CI: 0.68–0.99; $P=0.037$). The most common adverse effects were thrombocytopenia (27\%) and neutropenia (24\%). The US Food and Drug Administration did not approve the supplementary data. Results of the Phase III trials are pending. The end point for the azacitidine Phase III trial is OS. For decitabine, they are CR, OS, event-free survival (EFS), and RFS.\textsuperscript{46}

\textbf{Gemtuzumab ozogamicin}

Gemtuzumab ozogamicin (GO) is a monoclonal antibody directed against the CD33 cell surface antigen expressed on AML cells, conjugated to an antibiotic calicheamycin, which causes DNA strand break and cell death on internalization. GO was approved in the USA and Japan for the treatment of relapsed AML patients aged older than 60 years and ineligible for standard induction chemotherapy. GO was however subsequently withdrawn from the market due to increased risk of death during induction in a trial conducted after approval.\textsuperscript{47} The Phase III trial of GO alone in comparison with the best supportive care is pending results. This trial targets patients previously untreated but not eligible for intensive chemotherapy (NCT00091234).

In the Phase II monotherapy trial,\textsuperscript{48} CR, CRp, and PR (partial response) were achieved in 23\% of patients in both
treatment schedules, with an early mortality rate of 12%. Adverse effects included nausea, vomiting, diarrhea, stoma-
titis, and transient elevation in liver function tests.

The LRF AML14 and NCRI AML16 trials compared GO
plus LDAC with LDAC alone.59 GO plus LDAC improved
the response rate compared to LDAC alone (30% versus 17%;
HR: 0.48; 95% CI: 0.32–0.73; P=0.006). The 12-month OSs
were not different (27% versus 25%; HR: 0.99; 95% CI:
0.83–1.16; P=0.9). The 30-day mortalities were not different
(18% versus 16%).

Cell cycle inhibitor volasertib

The Polo-like kinases (Plks) consist of a family of five
serine-and-threonine kinases, with four being identified in
mammals.50–52 The first polo gene was isolated in 1991 by a
group working with the fruit fly Drosophila melanogaster.53
It was found that this gene encodes an enzyme, mutation
of which was associated with aberrant mitosis. Subsequent
work54,55 identified the murine and human homologs of the
fly gene, involved in cell proliferation. They were mainly
expressed in the hematopoietic progenitor cells, testes, and
ovaries in contrast to other tissues with low proliferation
rate. They were named polo-like kinases, Plks. The kinases
were homologous to the budding yeast Saccharomyces
Cerevisiae cell division cycle gene CDC5 and early growth
response gene SNK/PLK2; all belong to the big family of
serine-and-threonine kinases. The following section will
review efforts in bringing the Plk1 inhibitor volasertib to
the bedside for AML patients who cannot tolerate standard
induction chemotherapy.

PLK1 gene structure and function

Structurally, PLKs have two functional domains: the
N-terminal serine/threonine kinase catalytic domain and the
C-terminal regulatory domain(s).56,57 The catalytic domain
is where the serine/threonine kinase activity resides and has
an adenosine triphosphate (ATP)-binding pocket, to which
the small-molecule ATP-competitive kinase inhibitors are
directed. The regulatory domain consists of one to two
polo-box domains (PBDs). The PBD(s) inhibit the catalytic
domain when there is no binding of phosphopeptide. On
binding to the phosphopeptide of a phosphoprotein, the
PBD releases the kinase domain, allowing it to bind or
dock its substrate, thus setting off the signal transduction
cascade. The PLKs play essential roles in many impor-
tant cellular processes. These processes include mitosis,58
DNA replication,59 and stress response to DNA damage
and recovery,60–62 among other newly discovered ones such
as resistance to apoptosis63,64 and regulation of cancer cell
invasiveness.65 The role of PLK1 is the best studied. Its
essential roles in mitosis include mitotic entry, centrosomal
maturation, sister chromatid separation, mitotic exit, as well
as cytokinesis (Figure 1). The most prominent phenotype
occurring when PLK1 function is depleted is known as the
“polo-arrest” (Figure 2).66 When polo-arrest happens, there
is perturbation of the spindle assembly and cell cycle arrest
at the prometaphase. Mitotic cells accumulate with monopolar
spindles that are inappropriately attached to the kinetochores.
In the end, cells go into apoptosis.67

PLK1 as a valid target in cancer therapy

As stated herein, PLK1 is expressed in normal proliferating
cells. PLK1 is also frequently overexpressed in various
malignancies such as AML, non–small cell lung cancer
(NSCLC), breast cancer, prostate cancer, colorectal cancer,
pancreatic cancer, papillary thyroid cancer, ovarian
cancer, head and neck cancer, as well as in non-Hodgkin’s
lymphomas.68–71 Studies have also linked PLK1 overexpres-
sion to poor prognosis and survival. Therefore, it has long
been considered a valid target for cancer therapy.

Volasertib is a small-molecule Plk1
inhibitor

Volasertib (BI6727) belongs to the class of dihydropteri-
dinone derivative small-molecule ATP-competitive kinase
inhibitors.66 Volasertib was discovered by screening a library
of organic compounds capable of inhibiting Plk1 activity.
Although it is of the same class with BI253667,72 (also a
very potent, small-molecule dihydropteridinone derivative
ATP-competitive kinase inhibitor), volasertib has a different
chemical structure and was tailored from BI2536 based on the
principles of potency, selectivity, and efficacy in inhibiting
tumor growth in the xenograft tumor model.

Pharmacology of volasertib

Volasertib is potent and selective. It has a half-maximal
inhibitory concentration (IC$_{50}$) of 0.87 nM, 5.0 nM, and
56 nM toward Plk1, Plk2, and Plk3, respectively.66 Volasertib
had no appreciable inhibition to a panel of >60 other kinases
tested at a concentration as high as 10 M,73 asserting the high
selectivity of the drug. The half-maximal effective concentra-
tion (EC$_{50}$), which measures the potency of a drug in a battery
of cell lines, was between 11 nM and 37 nM. Cell lines used
in determining the EC$_{50}$ included lung cancer (H460), colon
(HCT116), melanoma (BRO), leukemia (HL60), and B-cell
lymphoma (Raji). The half-life ($T_{1/2}$) when tested in humans,
Figure 1 Functions of Plk1 during the cell cycle.
**Notes:** Dashed lines indicate the sites of action. Courtesy of Lynsey Ekema, MSMi Instructional Design and Development, Georgia Regents University.
**Abbreviations:** APC/C, anaphase-promoting complex/cyclosome; D, daughter cell; Plk, Polo-like kinase.

Figure 2 Volasertib blocks bipolar spindle formation, inducing cell cycle arrest in the M phase.
**Notes:** NCI-H460 NSCLC cells were treated for 24 hours with either (A) 0.1% DMSO or (B) 100 nM/L of volasertib. Cells were fixed, stained with either DAPI (to stain DNA; in blue) or anti-tubulin (to stain spindles; in green) and anti-phosphoSer10 histone H3 (in pink), and photographs taken under a fluorescence microscope. Volasertib treatment caused accumulation of mitotic cells with monopolar spindles. The kinetochores here were not properly attached to the spindle, i.e., they showed “Polo arrest.” Reprinted from American Association for Cancer Research, 2009, 15/9, 3094–3102, Dorothea Rudolph, Martin Steegmaier, Matthias Hoffmann et al., BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity, with permission from AACR.
**Abbreviations:** AACR, American Association for Cancer Research; DAPI, 4′,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; NCI, National Cancer Institute; NSCLC, non–small cell lung cancer.
was 111 hours, with a volume of distribution of >4,000 L. The clearance was moderate, at 792 mL/min. All these pharmacokinetic characteristics suggest very good tissue exposure to volasertib. The long half-life and large volume of distribution were also confirmed in an independent study in AML patients. The oral bioavailability is good across species: mouse (F: 41%), rat (F: 55%), and dog (F: 53%).

### Tolerability and safety

In the first-in-human study, volasertib was given in a dose escalation manner in a Phase I trial that treated 65 patients with progressive metastatic solid tumors. Of these, 51 patients were treated during the dose escalation phase and 14 others in the expansion cohort. Patients received a single 1-hour infusion of volasertib every 3 weeks (Q3W). The doses received ranged from 12 mg to 450 mg. Side effects were all mainly hematological and were reversible. Dose-limiting toxicity (DLT) started to appear when the dose was escalated to 300 mg. DLT mainly included neutropenia, thrombocytopenia, and febrile neutropenia. The most common drug-related adverse events were anemia (total: 22%; grade 3: 8%), neutropenia (total: 15%; grade 3/4: 14%), thrombocytopenia (total: 14%, grade 3/4: 14%), and fatigue (total: 15%, grade 3: 2%). The maximum tolerated dose (MTD) was initially determined to be 400 mg Q3W. However, during the expansion cohort, three out of ten patients had DLT. After dose de-escalation to 350 mg, there were again three out of five DLTs. Therefore, the recommended dose for Phase II was 300 mg. Fatigue, weight loss, and QT prolongation were the other DLTs encountered in the trial. Volasertib was well tolerated.

In another confirmatory Phase I study conducted in 59 Asian patients, DLTs were again thrombocytopenia, neutropenia, and febrile neutropenia. The MTD determined for the Q3W infusion was 300 mg and 150 mg for the Day 1/Day 8 Q3W schedule. Pharmacokinetic characteristics again showed a long $T_{1/2}$ of 135 hours, with a large volume distribution of >3,000 L and moderate clearance. Volasertib was again well tolerated.

In a Phase I study of volasertib proceeding the Phase II trial in combination with low-dose cytarabine (LDAC) in relapsed/refractory AML, volasertib was given in a dose escalation manner on Day 1 and Day 15 every 4 weeks (Q4W) alone or in combination with subcutaneous LDAC 20 mg bid on Days 1–10 Q4W in a dose de-escalation fashion. In the monotherapy arm, 29 patients (age range: 26–84 years, median: 71 years) were evaluated. Adverse effects were reported in eight patients, which were considered drug related (27.6%). The most common drug-related adverse effects were anemia (10.3%), thrombocytopenia, epistaxis, and nausea (6.9%). Grade 3/4 drug-related adverse effects included thrombocytopenia, anemia, diarrhea, mucositis, pneumonia, fungal pneumonia (grade 5), and neutropenia. DLTs were grade 4 pneumonia, fatal fungal pneumonia that arose in a patient receiving 150 mg of volasertib, and one case of grade 3 mucositis (at 400 mg). MTD was not reached at 500 mg. In the combination arm, MTD was determined to be 350 mg at Day 1 and Day 15 Q4W, with Ara-C given at 20 mg bid, subcutaneously, on Days 1–10. No drug interaction was observed after administration of Ara-C with volasertib. The combination with Ara-C is safe and well tolerated too. This conclusion was supported by further treatment of AML in the Phase II part of the study.

### Efficacy of volasertib

#### Preclinical evaluation in animal models

The efficacy of volasertib was first observed in human tumor xenograft models established from multiple human cancer cell lines (colon: HCT116, lung: H460, and taxane-resistant colon: CXB1) in nude mice. Multiple rounds of volasertib were given to animals at a frequency ranging from daily to once or twice a week either orally or intravenously for 6 weeks. In the colon cancer model, volasertib had similar efficacy at a total weekly dosage of 50 mg/kg. Similar results were obtained when animals received 20 mg/kg or 30 mg/kg of volasertib intravenously once a week whereas tumors in the control group were progressively larger, volasertib given at 20 mg/kg for two consecutive days per week for 5 cycles resulted in tumor regression. Volasertib delayed tumor growth in NSCLC. Furthermore, it was effective in inhibiting the taxane-resistant colon cancer model as well. Examination of the tumor tissue after volasertib treatment found a 13-fold increase in mitotic figures in the tumor compared to the control in a colon cancer model 24 hours later. Apoptosis, as demonstrated by the terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling (TUNEL) assay, increased 4.5 folds compared to tumor treated with vehicle only. When a mouse bearing the colon cancer was given a single dose of 35 mg/kg, a much higher tissue concentration of volasertib is reached (maximum of 32 μM 8 hours versus 7 μM 1 hour after administration). Volasertib concentration in the tissue was still 4 μM in the tissue compared to only 8 nM in the blood 168 hours (7 days) after the drug injection (500-fold difference).

#### Phase I studies in solid tumors

In the first Phase I study, three patients showed an objective response, all of them PR, by Response Evaluation Criteria.
In Solid Tumors (RECIST) criteria. Types of solid tumors included melanoma (12), NSCLC (10), colorectal cancer (8), soft tissue sarcoma (7), urothelial carcinoma (6), prostate cancer (4), and others (18). The melanoma patient who showed PR was administered the 300 mg once Q3W dosage. The patient had received cisplatin and dacarbazine followed by radiation therapy, before failure of ipilimumab occurred. The PR started from Cycle 2 and lasted till Cycle 9 (progression-free survival [PFS]: 207 days). One patient with urothelial cancer had PR from Cycle 2 to Cycle 16. This patient had a dose reduction to 300 mg from Cycle 2 onward after adverse effect was noted on getting 450 mg in Cycle 1. The patient was restarted on volasertib after tumor resection and received a total of 39 cycles; PFS was 403 days. This patient was also heavily treated with neoadjuvant gemcitabine/cisplatin with surgery on diagnosis, and then paclitaxel, capecitabine with investigational agent after recurrence. The third patient with PR was administered 300 mg of drug (decreased after the first course from 400 mg) for her ovarian cancer. She had a total of four cycles and PFS of 148 days. After recurrence, this patient received six cycles of carboplatin/paclitaxel with CR, four cycles of cisplatin intraperitoneally, six cycles of liposomal doxorubicin, letrozole, and topotecan before volasertib. It is also noted in this trial that one NSCLC patient at 300 mg dose had stable disease as the best response for 550 days. This patient had no response to cisplatin-based chemotherapy and then to taxotere, with progressive disease in both occasions. Forty percent of these patients had stable disease as the best overall response and 48% had clinical benefit.

In a separate Phase I study performed in 59 Asian patients, two more PRs were documented. One had urothelial carcinoma receiving 300 mg Q3W and another had melanoma receiving 150 mg at Day 1 and Day 8. The urothelial cancer patient received a total of 23 cycles, whereas the melanoma patient received 9 cycles. Stable disease was found in 44.1% patients as their best response.

Phase I/II studies in AML patients
In the Phase I part of the study, antileukemic activity was observed in patients who had received higher doses of $\geq$350 mg intravenously on Day 1 and Day 15 Q4W in the monotherapy arm. CR or CR with incomplete blood count recovery (CRi) was achieved in 4 of the 16 patients. In the combination arm with LDAC, 7 out of 32 patients treated achieved CR or CRi. Median OS was 551 days (range: 165–595 days).

In the randomized Phase II part comparing LDAC versus volasertib plus LDAC, 87 patients were treated in two arms. The response rate (CR and CRi) in the LDAC plus volasertib arm was 31% (13 of 42 patients) compared to 13.3% in the LDAC arm (6 out of 45 patients) (OR: 2.91, $p=0.052$). There was no apparent correlation between the white blood cell count or blast percentage in the bone marrow at presentation. Importantly, the response was observed across all cytogenetic groups (regardless of the group as per ELN classification, Wheatley risk group, or genetic mutations in FLT3/ITD, NPM1, as described for different risk groups of leukemia). The patients in the combination arm had significantly longer exposure to the study drug than the LDAC arm (309 days versus 214 days).

At the time of survival analysis, 77 of the 87 patients had died. EFS in patients receiving the LDAC and volasertib (n=42) was significantly longer than in patients receiving LDAC only (n=45) (5.6 months versus 2.3 months; HR: 0.57; 95% CI: 0.35–0.92; $p=0.021$). RFS was 18.5 months and 10.0 months for the combination group (n=13) and the LDAC-only group (n=6), respectively, suggesting longer duration of remission in the combination treatment group. The median OS for the combination group and the LDAC group were 8.0 months and 5.2 months, respectively (HR: 0.63; 95% CI: 0.4–1.00; $p=0.047$). Exploratory analyses comparing survival of patients in the same cytogenetic groups treated in the two arms showed benefit in adding volasertib. Of note, this trial was originally not powered to show the survival benefit. On the basis of these promising results, a Phase III randomized, placebo-controlled, double-blinded trial comparing LDAC with LDAC and volasertib in 660 patients (POLO-AML-2, NCT01721876) was initiated. Results are expected in early 2016.

As stated herein, Plk1 is an essential kinase in the cell cycle. Plk1 is overexpressed in a variety of neoplasms. Overexpression of Plk1 in tumors has been linked to poor outcomes. Volasertib is a specific inhibitor of Plk1; the question is whether volasertib is more effective in treating cancers that express higher levels of Plk1 than in treating those that express lower levels. The latest study using bone marrow biopsies from AML patients, leukemia cell lines, immortalized lymphoblastoid cell lines, and non-neoplastic cell lines treated with Plk1 inhibitor, however, showed uniform suppression of proliferation, followed by apoptosis regardless of Plk1 expression levels. Therefore, volasertib is more likely to offer an advantage for those patients whose uncontrolled cell proliferation in neoplasms poses the most serious threats to survival, eg, patients with AML having high leukocyte counts. The other side of the coin is that volasertib could cause some other unintended
consequence if proliferation of normal cells is tightly suppressed too. It is difficult to link the cell proliferation status with efficacy in other tumor types at this time due to the small number and variety of neoplasms studied in these early-phase clinical trials.

Conclusion
AML assumes an aggressive course and is rapidly fatal if left untreated. It is unfortunately more common in the elderly population, with median age of diagnosis being above 65 years. Although most clinical trials show that elderly patients benefit from intensive treatment, it is likely that most patients in these trials comprise a very selective group of patients and it is unlikely that these studies are representative of the patients in the general population. This notion is supported by a recent SEER/Medicare analysis, which shows that 60% of patients older than 66 years of age were not offered any treatment. Despite intensive search for alternative, low-intensiveness regimens for the elderly and infirm patients unable to tolerate the standard treatment, the ideal regimen that adds benefit to single agent cytarabine proved to be elusive. In addition, the safety and tolerability of various chemotherapy drugs continues to be the biggest hindrance to the treatment of AML. Volasertib offers a newer approach to the treatment of AML. The promising results seen in a Phase II study with very favorable safety profile in both the AML studies and the solid tumor trials make this one of the exciting drugs in the pipeline for the treatment of AML. The Phase III volasertib trial results will, hopefully, provide an answer shortly.

Acknowledgment
The authors thank Lynsey Ekema, Master of Science Medical Illustration Instructional Design and Development, Georgia Regents University, for her expert assistance in illustrating the cell cycle in Figure 1.

Disclosure
The authors report no conflicts of interest in this work.

References


